PRESS RELEASE

Grupo Biotoscana announces supply, distribution and license agreement with Basilea for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America

MONTEVIDEO – September 13, 2016 – Grupo Biotoscana SL (GBT), a leading biopharmaceutical company in Latin America, announced today that it has entered into a supply, distribution and license agreement with Basilea Pharmaceutica International Ltd. (Basilea) for Basilea’s antifungal CRESEMBA® (isavuconazole) and Basilea’s antibiotic Zevtera® (ceftobiprole) in 19 countries in Latin America including Brazil, Mexico, Argentina and Colombia.

GBT, which is majority-owned by private equity firm Advent International, has operations in 10 Latin American countries, including high-growth geographies such as Argentina, Brazil, Colombia, Chile, Mexico Ecuador and Peru. The company focuses on fast-growing market segments such as specialty care, rare diseases and biopharmaceuticals.

Under the terms of the agreement, GBT holds an exclusive license to commercialize isavuconazole and ceftobiprole in Latin America. GBT will be responsible for marketing authorization applications, market access, commercialization and distribution of isavuconazole and ceftobiprole in the countries covered by the agreement.

Mariano García-Valiño, GBT’s CEO, stated: “We are very pleased to initiate a partnership with global anti-infective leader Basilea and to bring to Latin America isavuconazole and ceftobiprole, two innovative anti-infective molecules that could provide doctors and patients with novel treatment options for addressing the medical problem of increasing resistance in the areas of fungal and bacterial infections”.

About isavuconazole
Isavuconazole is an intravenous (i.v.) and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate. It was approved in March 2015 by the United States Food and Drug Administration (FDA) for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis.1 The European marketing authorization was granted in October 2015 to isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.1 Isavuconazole has orphan drug designation for the approved indications in Europe and the US. Basilea commercializes isavuconazole as CRESEMBA® in Germany, Italy, the UK and Austria. The drug is commercialized in the US by Basilea's licensee Astellas Pharma US. Outside the US and the EU, isavuconazole is not approved for commercial use.

About invasive aspergillosis and mucormycosis
Invasive aspergillosis and mucormycosis are life-threatening fungal infections that predominantly affect immunocompromised patients, such as patients with cancer. Invasive aspergillosis is known for high morbidity and mortality. Mucormycosis (also known as zygomycosis) is a rapidly progressing and life-threatening invasive fungal infection, known for high morbidity and mortality.
About ceftobiprole
Ceftobiprole is a broad-spectrum intravenous antibiotic from the cephalosporin class for i.v. administration with bactericidal activity against certain Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp. Ceftobiprole is approved for sale in 13 European countries and several non-European countries for the treatment of adult patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). The drug is currently available in Germany, Italy, the United Kingdom, France, Austria and Switzerland.

About hospital-acquired and community-acquired pneumonia
Hospital-acquired pneumonia (HAP) is one of the most common hospital-acquired infections and has been shown to have among the highest mortality rates of all hospital-acquired infections. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most frequent causes of hospital-acquired pneumonia. Community-acquired pneumonia (CAP) is a common condition with up to 60% of the patients requiring hospital admission and intravenous antibiotics. Prompt empiric intervention with an appropriate broad-spectrum antibiotic treatment is considered a best medical practice. The increasing incidence of bacteria resistant to many established antibiotics is a major concern.

About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea’s website www.basilea.com

About Grupo Biotoscana
Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast growing Latin American region and focuses on rapidly growing market segments such as oncology, hematology, high-complexity genetic disorders, rare disease, infectious disease, HIV and other specialty treatments. GBT operates throughout Latin American countries under the name of its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products with annual revenues of US$250 million. GBT is controlled by global private equity firm Advent International, with other significant shareholders including Essex Woodlands and a number of private investors. Additional information can be found at GBT’s website www.grupobiotoscana.com

#    #    #
Contacts:

In the US:

Advent International
Chuck Dohrenwend / Dana Gorman
Abernathy MacGregor (New York)
Tel: +1 212 371 5999
adventinternational@abmac.com

Essex Woodlands
Anne B. DeMaret
Investor Relations
Tel: +1 281 528 1956
ademaret@ewhv.com

In Latin America:

Raul Fagundes Neto / Fernando Marchi
Medialink (São Paulo)
Tel: +55 11 3817 2131
raul.fagundes@medialink.com.br

References

2. CRESEMBA® US prescribing information [Accessed: August 16, 2016]
4. European trade name Zevtera® or Mabelio®, depending on the country. The drug has received national licenses in 13 European countries for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP): Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Spain, Sweden, Switzerland and the United Kingdom.